SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is experiencing a sharp sell-off after reporting mixed Q4 earnings, where a revenue miss and conservative forward guidance overshadowed its profitability. The community is actively debating whether the market's strong negative reaction is an overdone response to broader fintech sector and macro credit concerns, or if it reflects justified apprehension regarding the company's cautious outlook.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group (CRDO) is surging after pre-announcing preliminary Q3 revenue significantly above prior guidance and consensus, coupled with a robust outlook for sequential growth into fiscal year 2027. The community is vigorously discussing this strong performance, highlighting its crucial role in the ongoing AI data center buildout and the massive capital expenditure increases from hyperscalers, expecting continued upward momentum.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending after the FDA issued a Complete Response Letter for its RGX-121 gene therapy for Hunter syndrome, citing concerns with trial design, external controls, and surrogate endpoints, amplifying broader sector scrutiny on gene therapies. The community is sharply divided, with some anticipating significant further declines and others believing the company's other pipeline assets retain substantial long-term value.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

FISV is trending intensely ahead of its earnings, with the community sharply divided between those anticipating a strong rebound fueled by perceived undervaluation, recent institutional accumulation, and new leadership's strategic moves, and those fearing another significant drop due to past disappointments, heavy put option activity, and ongoing fintech sector concerns.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl (KD) is in focus following the abrupt departure of its CFO and general counsel amidst an accounting review and delayed regulatory filings, triggering a severe sell-off. The community is debating whether the IT infrastructure provider's over 50% stock drop is an extreme overreaction and a buying opportunity, or a justified response to serious governance concerns.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending following its robust Q4 earnings beat, though a mixed Q1 outlook is fueling debate among investors between short-term caution and long-term optimism regarding its pivotal role in advanced AI and data center packaging, bolstered by strategic investments and CHIPS Act funding.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Satellos Bioscience (MSLE) is generating significant buzz following its Nasdaq listing, a recent financing round, and a reverse stock split, sparking an active community debate on the revolutionary potential of its SAT-3247 drug for Duchenne muscular dystrophy against concerns regarding dilution and the early stage of its clinical development.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is trending due to recent exchange listings and its expansion to the Solana blockchain, significantly increasing its accessibility and multi-chain utility. The community is actively discussing its AI agent-powered utility on the Base ecosystem, with many anticipating a significant price appreciation while others warn of potential volatility.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

CRO is trending following news of Trump Media's ($DJT) partnership with crypto.com/us for digital token distribution on the Cronos chain, with discussions also highlighting its potential inclusion and significant weighting in a proposed Crypto ETF. This development is driving considerable community debate, with some anticipating substantial growth while others express skepticism about the coin's future trajectory.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is trending lower after its latest earnings report, with disappointing Q1 guidance overshadowing beats on Q4 figures and positive long-term projections. The community is actively debating whether the significant price drop is an overreaction or signals deeper concerns about AI's impact on the gig economy and the company's future growth trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tevogen Bio (NASDAQ:TVGN) Shares Down 6.4% - Here's Why

Tevogen Bio (NASDAQ:TVGN) Shares Down 6.4% - Here's What Happened...

Tevogen Bio (NASDAQ:TVGN) Trading Down 1.8% - Time to Sell?

Tevogen Bio (NASDAQ:TVGN) Trading Down 1.8% - Here's What Happened...

Tevogen Bio (NASDAQ:TVGN) Price Target Cut to $5.00 by Analysts at D. Boral Capital

D. Boral Capital decreased their target price on shares of Tevogen Bio from $10.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday...

Tevogen Bio (NASDAQ:TVGN) Announces Earnings Results

Tevogen Bio (NASDAQ:TVGN - Get Free Report) posted its earnings results on Friday. The company reported ($0.03) earnings per share for the quarter...

Buy When There’s Blood in the Streets: Why the DeepSeek Rout May Be Good News for Microsoft Stock

Microsoft’s stock presents a buying opportunity due to its strong financials, strategic partnerships, and potential to benefit from cheaper AI models in the long run.

Shares of Tevogen Bio Holdings Inc. ($TVGN) spiked as much as 49% on Wednesday (1:34 pm ET), the highest in six months, after the pharmaceutical company announced an AI-related partnership with Microsoft Corp. ($MSFT) for Startups, lifting retail sentiment.The partnership marks a “significant milestone” for the Warren, N.J.-based company as it is aimed at accelerating and streamlining the development of Tevogen’s proprietary algorithms, and lower the total cost of drug development and expedite drug discovery. Tevogen, founded in 2020, has said it owns three patents, with nine pending U.S. and 12 international applications.Retail sentiment on the stock turned ‘bullish’ (72/100) from ‘neutral’ (48/100) a day ago with accompanying message volumes remaining in the ‘high’ zone. (65/100).<figure class="image"><img style="aspect-ratio:1308/370;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_23_at_11_05_18_PM_653412ce71.png" alt="Screenshot 2024-10-23 at 11.05.18 PM.png" width="1308" height="370"><figcaption>TVGN sentiment meter as of 1:35 pm ET| Source: Stocktwits</figcaption></figure>Tevogen develops off-the-shelf therapies that treat infectious diseases, cancers, and neurological disorders.It has previously made projections to reach $1 billion in revenue for its first year from its cancer drugs, with a cumulative five-year estimate of $10 billion - $14 billion on its revenue.Tevogen previously reported positive safety outcomes from the clinical trial for its first product TVGN 489, a T-cell therapeutic for high-risk Covid-19 patients including immunocompromised and the elderly. One Stocktwits user predicted its stock to close above $2.40<stembedurl>https://stocktwits.com/Nearthend/message/589853427</stembedurl><stembedurl>https://stocktwits.com/Nickprice864/message/589854161</stembedurl>Tevogen stock is up 52% year-to-date.

Tevogen Bio Shares Surge After AI Tie-Up With Microsoft: Retail Turns Bullish

The partnership marks a “significant milestone” to lower the total cost of drug development, the company said

Equity

The partnership marks a “significant milestone” to lower the total cost of drug development, the company said.

Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. It focuses on its product, ExacTcell, a technology that treats acute viral infections, long-term consequences of viral infections, and viral and non-viral induced cancers. The company was founded in April 2021 and is headquartered in Warren, NJ.

Tevogen Bio Holdings Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.03	--	--	N/A
Q3 '25	-$0.06	-$0.03	50.66%	BEAT
Q2 '25	-$0.03	-$0.03	-2.00%	MISSED
Q1 '25	-$0.05	--	--	N/A
Q4 '24	-$0.03	--	--	N/A

TVGN
Tevogen Bio Holdings Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest TVGN News

TVGNTevogen Bio Holdings Inc.